Novan (NOVN) Gets a Buy Rating from H.C. Wainwright

H.C. Wainwright analyst Oren Livnat reiterated a Buy rating on Novan (NOVN) today and set a price target of $20.00. The company’s shares closed last Thursday at $9.04.

According to, Livnat is a 4-star analyst with an average return of 7.7% and a 48.7% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Satsuma Pharmaceuticals, and Zynerba Pharmaceuticals.

Currently, the analyst consensus on Novan is a Moderate Buy with an average price target of $25.00.

See today’s analyst top recommended stocks >>

Based on Novan’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $819K and GAAP net loss of $8.95 million. In comparison, last year the company earned revenue of $1.21 million and had a GAAP net loss of $6.17 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Novan, Inc. is a biotechnology company, which engages in leveraging nitric oxide’s natural antiviral and immunomodulatory mechanisms of action to treat dermatological and oncovirus-mediated diseases. Its products pipeline include SB204, SB206, SB208, and SB414. The company was founded by Mark Schoenfisch and Nathan Stasko in 2006 and is headquartered in Morrisville, NC.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts